PR Newswire Clinical TrialsOriginal article
Precision Radiation Therapy Alone Doubles Historical Survival Rates for Inoperable Lung Cancer, Landmark Lancet Trial Finds
Phase 3positiveProton TherapyPositive
AI Analysis
Summary
A Phase III trial published in Lancet demonstrates that precision proton radiation therapy alone achieves an 82% two-year survival rate for inoperable lung cancer patients, approximately doubling historical survival benchmarks. The trial was led by researchers from the New York Proton Center.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
82% two-year survival rate, doubling historical survival rates for inoperable lung cancer
Importance:7/10
Sentiment:
0.85
Phase_3_DataProton_TherapyLung_CancerClinical_TrialSurvival_Benefit
Read the original article
Published by PR Newswire Clinical Trials on September 24, 2026 12:01 PM